What BELITE BIO, INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 50 | 179 |
| Total trades | 53 | 184 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 184 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Scholl Hendrik Peter | Chief Medical Officer | Nov 12 | Disclosed 10b5-1 sale · S | −500 | $170.41 | −$85.2K | 12,500 |
| Scholl Hendrik Peter | Chief Medical Officer | Nov 12 | Disclosed 10b5-1 sale · S | −500 | $166.82 | −$83.4K | 13,000 |
| Scholl Hendrik Peter | Chief Medical Officer | Nov 12 | Disclosed 10b5-1 sale · S | −500 | $164.68 | −$82.3K | 13,500 |
| Scholl Hendrik Peter | Chief Medical Officer | Nov 12 | Disclosed 10b5-1 sale · S | −500 | $162.04 | −$81K | 14,000 |
| Lin Yu-Hsin | Chief Executive Officer | Oct 29 | Other Transaction · J | +5,000 | — | — | 187,949 |
| Chuang Hao-Yuan | Chief Financial Officer | Oct 29 | Other Transaction · J | +5,000 | — | — | 180,264 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −2 | $170.02 | −$340 | 14,500 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −14 | $169.36 | −$2.37K | 14,502 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −12 | $168.21 | −$2.02K | 14,516 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −78 | $167.59 | −$13.1K | 14,528 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −50 | $166.44 | −$8.32K | 14,606 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −120 | $165.49 | −$19.9K | 14,656 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −24 | $164.64 | −$3.95K | 14,776 |
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 | Disclosed 10b5-1 sale · S | −200 | $163.63 | −$32.7K | 14,800 |
| Chen Wan-Shan | Director | Sep 24 | In/At-money Exercise · X | +13,796 | $0.44 | +$6.05K | 37,259 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 08 | Disclosed 10b5-1 sale · S | −2,700 | $198.09 | −$535K | 70,134 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 08 | Disclosed 10b5-1 sale · S | −8,752 | $197.36 | −$1.73M | 72,834 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 08 | Disclosed 10b5-1 sale · S | −6,058 | $196.54 | −$1.19M | 81,586 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 08 | Disclosed 10b5-1 sale · S | −6,090 | $195.62 | −$1.19M | 87,644 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 08 | Disclosed 10b5-1 sale · S | −2,400 | $194.33 | −$466K | 93,734 |
Loading...